GRI Bio (GRI) Short-term Investments (2021 - 2022)
GRI Bio (GRI) posted quarterly Short-term Investments of $419000.0 for Q3 2022, down 87.12% year-over-year from $3.3 million in Q3 2021, and down 76.04% quarter-over-quarter from $1.7 million in Q2 2022.
GRI Bio (GRI) Short-term Investments (2021 - 2022) Analysis & Trends
GRI Bio's Short-term Investments history runs 2 years deep, the most recent figure standing at $419000.0 for Q3 2022.
- In Q3 2022, Short-term Investments fell 87.12% year-over-year to $419000.0; the TTM figure through Sep 2022 stood at $419000.0 (down 87.12% YoY), while the FY2021 annual figure was $3.8 million, changed N/A from the prior year.
- Short-term Investments for Q3 2022 stood at $419000.0, down from $1.7 million in the prior quarter.
- The five-year high for Short-term Investments was $3.8 million in Q4 2021, with the low at $419000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | GRI Bio | 3.01 Mn | 3.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 419,000.00 |
| Jun 30, 2022 | 1.75 Mn |
| Mar 31, 2022 | 2.63 Mn |
| Dec 31, 2021 | 3.81 Mn |
| Sep 30, 2021 | 3.25 Mn |